Pittock Sean J, McClelland Robyn L, Mayr William T, Jorgensen Neal W, Weinshenker Brian G, Noseworthy John, Rodriguez Moses
Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Ann Neurol. 2004 Aug;56(2):303-6. doi: 10.1002/ana.20197.
In 2001, we followed up all patients from the 1991 Olmsted County Multiple Sclerosis (MS) prevalence cohort. We found that the longer the duration of MS and the lower the disability, the more likely a patient is to remain stable and not progress. This is particularly powerful for patients with benign MS with Expanded Disability Status Scale score of 2 or lower for 10 years or longer who have a greater than 90% chance of remaining stable. This is important because these patients represent 17% of the entire prevalence cohort. These data should assist in the shared therapeutic decision-making process of whether to start immunomodulatory medications.
2001年，我们对1991年奥姆斯特德县多发性硬化症（MS）患病率队列中的所有患者进行了随访。我们发现，MS病程越长且残疾程度越低，患者保持病情稳定且不进展的可能性就越大。对于良性MS患者，扩展残疾状态量表评分在2分或更低且持续10年或更长时间的患者，这种情况尤为明显，他们保持病情稳定的几率超过90%。这一点很重要，因为这些患者占整个患病率队列的17%。这些数据应有助于在是否开始免疫调节药物治疗的共同决策过程中提供参考。
